Core Viewpoint - The event hosted by Shanghai Shenshi Medical Beauty Hospital focuses on integrating traditional Chinese medicine with skincare, emphasizing the importance of natural, safe, and long-lasting skincare solutions in response to evolving consumer demands [1] Group 1: Event Overview - Shanghai Shenshi Medical Beauty Hospital held a skincare salon themed "Inheriting Traditional Chinese Wisdom, Protecting Skin Health" [1] - The salon attracted executives from multiple listed companies, highlighting its significance in the industry [1] Group 2: Skincare Insights - A senior beauty TCM doctor used the winter solstice as a starting point to educate attendees on skincare, noting that skin tends to become dry and dull during this period, and emphasized the "nourishing and storing" principle [1] - The doctor demonstrated relevant therapies and shared practical daily methods for skincare [1] Group 3: Company Strategy - Shanghai Shenshi Medical Beauty Hospital is a key initiative of Shanghai Industrial (Group) Co., Ltd., aligning with the Healthy China and Healthy Shanghai strategies [1] - The hospital collaborates with experts from Shanghai Jiao Tong University School of Medicine and the Ninth People's Hospital to contribute to the multi-tiered healthcare system in Shanghai and the development of an Asian medical center [1] Group 4: Educational Purpose - The salon serves as a platform for sharing achievements in the field of TCM skincare and aims to educate the public on traditional health and skincare knowledge [1] - The initiative is designed to promote the upgrade of health consumption concepts by integrating traditional wellness practices into daily life [1]

Macro Insights - October CPI turned positive year-on-year, exceeding market expectations, driven by the weakening high base effect, seasonal food price increases, holiday effects, and medical price reforms impacting service prices [2] - PPI recorded its first month-on-month increase this year, attributed to improved supply-demand dynamics in industrial products and rising international metal prices [2] Trade Data - In October 2025, China's exports fell by 1.1% year-on-year, significantly down from the previous month, primarily due to high base effects. Integrated circuits and automobiles were key export drivers, while labor-intensive products contributed negatively [3] - The export growth rate is expected to remain affected by high base effects in the remaining months of the year, but supportive non-US economies and easing US-China trade relations are likely to maintain a favorable export outlook [3] Market Strategy - The current market position is seen as a potential starting point for a long-term bull market, with gradual improvements in fundamentals and industry highlights as the foundation. The inflow of resident funds and policy support will influence market trends [4][10] - The market may enter a wide-ranging consolidation phase in the short term, with a focus on defensive and consumer sectors, while mid-term attention remains on TMT and advanced manufacturing sectors [10] Bond Market - The secondary market for REITs showed a downward trend, with the weighted REITs index closing at 182.3, reflecting a return rate of -0.48% for the week [5] - Credit bond issuance totaled 334 bonds with a total scale of 363.4 billion yuan, a decrease of 7.66% week-on-week, while industrial bonds saw a 5.36% increase in issuance [6] Industry Research TMT Sector - The narrative around AI investments is shifting from "need to invest" to "need for returns," leading to a revaluation of AI visibility and realization. Major tech companies are experiencing accelerated growth in cloud computing revenue, validating AI demand [11] - Recommended stocks include Microsoft, with a focus on Google, Amazon, and Meta [11] Basic Chemicals - Strong demand for energy storage is tightening the supply-demand situation for iron phosphate, leading to improved prices and profitability for leading phosphate chemical companies [12] - Suggested stocks include Yuntianhua, Chuanheng, and Xingfa Group [12] Oil and Gas - OPEC+ announced a pause in production increases, which is expected to alleviate concerns over oil supply. Geopolitical tensions are likely to support oil prices [13] - The report highlights risks related to upstream capital expenditure growth and price volatility [13] Food and Beverage - Recommendations include strong brands with high dividend returns like Kweichow Moutai and Shanxi Fenjiu, as well as companies benefiting from structural upgrades in the beer sector [14] - Suggested stocks include Yihai International and Mengniu Dairy [14] Automotive - The automotive market showed strong performance in October, with NIO's monthly sales surpassing 40,000 units. Recommended stocks include NIO and XPeng Motors [15] - Suggested components include Fuyao Glass and Wuxi Zhenhua [15] Textile and Apparel - The textile and apparel sector is focusing on mitigating tariff impacts and enhancing market share among leading companies. Recommended stocks include Shenzhou International and Anta Sports [16] - The cosmetics sector is expected to highlight the capabilities of leading companies amid intensified competition [16] Company Research Hong Kong Stock Exchange - The company reported record high revenue and profit for the first three quarters of 2025, driven by active trading in the Hong Kong stock market [17] - The forecast for net profit from 2025 to 2027 is 17.3 billion, 18.5 billion, and 19.5 billion HKD, maintaining a "buy" rating [17] Farah Electronics - The company achieved a revenue of 1.445 billion yuan in Q3 2025, with a year-on-year growth of 9.31%. The market share in the new energy sector continues to rise [18] - The stock is rated as a "buy" with a projected PE of 20X, 16X, and 14X for 2025-2027 [18] Huahong Semiconductor - The company is entering a price increase cycle due to sustained demand recovery, with adjusted net profit forecasts for 2025-2027 of 70 million, 150 million, and 190 million USD [19] - The stock is rated as a "buy" based on market share growth and long-term revenue potential [19] Meili Tianyuan Medical Health - The acquisition of Siyanli is expected to enhance the company's performance, with revised net profit forecasts for 2025-2027 of 320 million, 440 million, and 490 million yuan [20] - The stock is rated as a "buy" with a focus on shareholder returns [20]

Group 1 - The North Exchange 50 Index and the Specialized and Innovative Index will undergo adjustments on December 15, 2025, with the North Exchange 50 Index experiencing its fourth adjustment and the Specialized and Innovative Index its first adjustment [10][12][15] - The North Exchange 50 Index closed at 1,522.73 points, reflecting a weekly decline of 3.79%, while the Specialized and Innovative Index closed at 2,532.06 points, down 5.43% [31][32] - The report emphasizes the importance of focusing on high-quality stocks and technology growth within the North Exchange 50 components, particularly those that have undergone significant price adjustments [3][42] Group 2 - The report identifies potential new additions to the North Exchange 50 Index, including companies such as Kaifa Technology, Gobika, and Wantong Hydraulic, with a focus on their average market capitalization and trading volume [12][13] - The North Exchange Specialized and Innovative Index is expected to include companies like Star Map Measurement and Senxuan Pharmaceutical, highlighting their market performance and growth potential [15][16] - The report suggests that the North Exchange's valuation structure shows a significant number of companies with high P/E ratios, indicating a potential investment opportunity in undervalued stocks [21][36][41] Group 3 - The report indicates that the average P/E ratio for key sectors such as high-end equipment, information technology, and chemical new materials are 42.83X, 91.31X, and 48.18X respectively, suggesting varying levels of valuation across industries [36][41] - The North Exchange's market performance shows a decline in trading volume, with an average daily turnover of 230.88 billion yuan, down 20.36% from the previous week [26][30] - The report highlights the importance of monitoring companies with strong quarterly performance and reasonable valuations as the North Exchange approaches its index adjustments [42][43]

Investment Rating - The report assigns a rating of "Buy" to the company [4]. Core Insights - The company has demonstrated strong growth in new orders for Q3 2025, primarily driven by performance in the Chinese, Korean, and Thai markets. The flagship multi-functional device, Alma Harmony, has shown robust growth, contributing to a double-digit year-on-year increase in unaudited revenue for the quarter [1][2]. - The injection filling business has seen a remarkable growth of 218% in the first half of 2025, showcasing strong product capability and channel layout. The long-acting botulinum toxin, DaxibotulinumtoxinA (DAXXIFY), is progressing smoothly towards its expected launch in China [3][19]. - The penetration rate of botulinum toxin in the Chinese market remains below the global average, indicating significant growth potential. The company is well-positioned to capitalize on this opportunity with its DAXXIFY product, which has already seen rapid revenue growth in the U.S. market [4][29]. Summary by Sections Energy Source Equipment - The demand for energy source equipment in the Asia-Pacific market is strong, with new orders showing double-digit growth in Q3. The company’s energy source equipment business has rebounded significantly in Q3 2025 after facing challenges earlier in the year due to high interest rates and geopolitical tensions affecting North America [2][13]. - The flagship device, Alma Harmony, launched globally in March 2025, has received a strong market response, further boosting order volumes. The Soprano series laser devices have also performed well, particularly after the successful launch of "Titan Lift" in China [2][13]. Injection Filling - The injection filling business, particularly the hyaluronic acid products, has shown strong growth, with the company planning to enhance the promotion of Profhilo in Thailand and expand Revanesse sales in the UK, German-speaking regions, Australia, and New Zealand [3][19]. - The anticipated approval and launch of DAXXIFY in September 2024 is expected to inject new growth momentum into the injection filling business [3][19]. Botulinum Toxin - The Chinese botulinum toxin market is projected to grow steadily, with an expected market size of 14.3 billion yuan by 2025, reflecting a CAGR of 26% from 2019 to 2025. The current penetration rate of botulinum toxin in China is significantly lower than the global average, indicating ample room for growth [20][25]. - The company’s DAXXIFY product, which utilizes proprietary peptide exchange technology, is expected to achieve rapid market penetration in China due to its long-lasting effects and high safety profile [29][25]. Financial Forecast and Investment Recommendations - The company is projected to achieve revenues of $382 million, $442 million, and $510 million for 2025, 2026, and 2027, respectively, with corresponding net profits of $29 million, $36 million, and $45 million. The earnings per share (EPS) are expected to be $0.06, $0.08, and $0.10 for the same years [8][36]. - The report emphasizes that the energy source equipment business is expected to stabilize and recover, while the injection filling business is likely to see significant contributions from the upcoming DAXXIFY launch [8][35].

Market Overview - The medical beauty sector experienced a decline of 0.93% on November 7, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - The closing prices and performance of key stocks in the medical beauty sector are as follows: - *ST Meigu: Closed at 4.02, up 1.77% with a trading volume of 143,600 shares and a turnover of 57.01 million yuan [1] - Jinbo Biological: Closed at 234.00, up 0.02% with a trading volume of 7,738.5 shares and a turnover of 1.83 billion yuan [1] - Huaxi Biological: Closed at 49.78, down 0.04% with a trading volume of 17,300 shares and a turnover of 86.15 million yuan [1] - Ai Meike: Closed at 149.16, down 1.87% with a trading volume of 30,900 shares and a turnover of 465 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 46.6453 million yuan from main funds, while retail investors contributed a net inflow of 34.3979 million yuan [1] - The capital flow for key stocks is as follows: - *ST Meigu: Net outflow of 2.6832 million yuan, down 4.71% [2] - Huaxi Biological: Net outflow of 3.3342 million yuan, down 3.87% [2] - Ai Meike: Net outflow of 40.6279 million yuan, down 8.74% [2]

Investment Rating - The industry investment rating is "Outperform the Market" with an expected relative increase of over 10% in the next six months [25]. Core Insights - The fund allocation ratio for the beauty and personal care industry decreased in Q3 2025, with a total market capitalization of 284.799 billion yuan, reflecting a 2.79% increase from Q2 2025. The fund's total holdings in the beauty and personal care sector amounted to 6.796 billion yuan, resulting in a fund allocation ratio of 0.20%, which is a decrease of 0.12 percentage points from Q2 2025, indicating a continued underweight position [2][11]. - The medical beauty sub-sector is currently in an overweight position, while personal care and cosmetics are underweight. The fund allocation ratio for personal care products was 0.04% in Q3 2025, down 0.04 percentage points from the previous quarter. The cosmetics sector also saw a decline, maintaining a fund allocation ratio of 0.04% in Q3 2025, down 0.02 percentage points [3][16]. - The top three stocks by fund holding in Q3 2025 are Jinbo Biological, Aimeike, and Baiya Shares, with a total holding ratio of 0.07%, which is a decrease of 0.04 percentage points from Q2 2025 [4][18]. Summary by Sections Industry Overview - In Q3 2025, the beauty and personal care industry fund allocation ratio decreased to 0.20%, with an underweight ratio of -0.09%, indicating a continued low allocation [2][11]. Sub-sector Analysis - Medical Beauty: The fund allocation ratio peaked at 0.53% in Q4 2022 but has since declined to 0.12% in Q3 2025, with an overweight ratio of 0.03% in Q2 2025 [3][16]. - Personal Care: The fund allocation ratio was at a historical low from Q3 2021 to Q3 2022, with a slight recovery post-Q4 2022. The current ratio is 0.04%, indicating a shift from positive to negative overweight [3][16]. - Cosmetics: The fund allocation ratio has been declining since Q3 2022, currently at 0.04%, with an overweight ratio of -0.09% [3][16]. Stock Holdings - The top three stocks in the beauty and personal care sector by fund holding in Q3 2025 are Jinbo Biological (0.0254%), Aimeike (0.0195%), and Baiya Shares (0.0051%), all showing a decline in holding ratios compared to Q2 2025 [4][21]. Investment Recommendations - The report suggests focusing on cosmetics and medical beauty sectors due to significant demand potential in the long term, driven by the "beauty economy." It also highlights the importance of compliance and strong R&D capabilities in personal care products [5][24].

Group 1 - The medical beauty sector increased by 0.18% on November 6, with *ST Meigu leading the gains [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] - The trading volume and turnover for *ST Meigu were 137,900 hands and 53.13 million yuan, respectively, with a price increase of 3.95% [1] Group 2 - The medical beauty sector experienced a net outflow of 34.96 million yuan from main funds, while retail investors saw a net inflow of 36.62 million yuan [1] - Individual stock performances included *ST Meigu with a 3.95% increase, Aimeike with a 0.38% increase, Huaxi Biological with a 0.52% decrease, and Jinbo Biological with a 2.54% decrease [1] - The net fund flow for *ST Meigu was -3.52 million yuan, indicating a decrease of 6.63% [2]

Core Viewpoint - The A-share market experienced a collective decline, with the Shanghai Composite Index down 0.44%, Shenzhen Component Index down 0.84%, and ChiNext Index down 1.04. The medical device ETF showed resilience, increasing by 1.00% amid mixed performances from constituent stocks, highlighting potential growth in the medical device sector driven by regulatory approvals and market trends [1]. Group 1: Market Performance - The medical device ETF (562600) rose by 1.00%, with the latest price at 0.91 yuan and a trading volume of 0.14 billion yuan, reflecting a turnover rate of 6.14% [1]. - The medical device ETF has seen a scale increase of 0.42 billion yuan over the past week, reaching a new high since its launch [2]. - The medical device ETF has recorded net inflows for six consecutive trading days, with a maximum single-day net inflow of 0.15 billion yuan, totaling 0.48 billion yuan in net inflows [2]. Group 2: Company Developments - Lepu Medical's subsidiary received regulatory approval for a rechargeable implantable deep brain stimulation (DBS) system, marking a significant breakthrough in China's neuroregulation field and expected to enhance performance while mitigating the impact of centralized procurement [1]. - The global DBS market is anticipated to grow rapidly, with an increasing trend towards alternatives [1]. Group 3: Valuation and Sector Composition - The latest price-to-earnings ratio (PE-TTM) for the medical device ETF is 47.48, which is below the 63.83% percentile of the past decade, indicating a moderate valuation [2]. - The ETF's index weight is heavily concentrated in the pharmaceutical and biological sectors (95.14%), with smaller allocations to beauty care (4.60%) and light manufacturing (0.26%) [2]. - Within the secondary industry classification, the ETF's index weight is primarily in medical devices (90.28%), followed by medical services (4.36%) and medical beauty (3.30%) [2].

十月二十九日，直达韩国仁川港的"泛奥升奥普轮"（右）在青岛港前湾港区装卸集装箱（无人机照 片）。新华社记者 李紫恒摄 10月30日至11月1日，国家主席习近平应邀赴韩国庆州出席亚太经合组织（APEC）第三十二次领导人 非正式会议并对韩国进行国事访问。 连日来，旅居韩国的华侨华人持续热议APEC会议上的中国声音。在接受本报记者采访时，多位侨胞分 享了亲身参与双多边合作的经历，对即将到来的APEC"中国年"满怀期待，表示将继续发挥侨力，为中 韩合作架桥、为亚太发展添彩。 关注APEC会议释放积极信号 除传统贸易与投资外，中韩在人工智能、新能源、文化旅游、生物科技等领域的合作活力日益凸显 最近，韩国浙江商会会长、全博集团董事长张益波完成了一项重要签约——与韩中总商会签署全面合作 协议。其中，储能储电等新能源技术是双方合作的一个重点。 本次APEC会议上，中方提出强化数智赋能、坚持绿色低碳、落实普惠共享等主张，给张益波留下了深 刻印象，也坚定了他继续推进绿色及高新技术产业合作的信心。目前，他正全力筹备浙江专精特新"小 巨人"企业代表团赴韩考察事宜。"考察团将走访韩国多家科技企业及高校，对接新能源、智能制造等领 域的先 ...

Financial Performance - In the first three quarters of 2025, the company achieved total revenue of approximately 4.328 billion yuan, a year-on-year increase of 0.89% [2] - Gross profit margin reached 59.35%, an increase of 1.77 percentage points compared to the same period last year [2] - Net profit attributable to shareholders was approximately 366.95 million yuan, a year-on-year increase of 0.5% [2] - Net cash flow from operating activities was approximately 359 million yuan, a year-on-year decrease of 1.87% [2] - Basic earnings per share were 2.2346 yuan, a year-on-year increase of 366.90% [2] - Total assets were approximately 8.617 billion yuan, a year-on-year increase of 5.67% [3] - Net assets attributable to shareholders were approximately 3.413 billion yuan, a year-on-year increase of 19.07% [3] Business Segment Performance - Medical beauty segment revenue was approximately 2.237 billion yuan, a year-on-year increase of 2.49% [3] - Women's clothing segment revenue was approximately 1.407 billion yuan, a year-on-year increase of 0.08% [3] - Infant and child segment revenue was approximately 674 million yuan, a year-on-year decrease of 1.58% [3] Investment Activities - The company generated investment income of approximately 970 million yuan from the disposal of part of its equity in Ruoyuchen [4] - The company acquired 67.50% of Chongqing Milan Baiyu Time Aesthetic Hospital for 92.475 million yuan, with a valuation dynamic price-earnings ratio of 13.38 times [4][5] - Performance commitments for Chongqing Time's net profit are set at no less than 9.29 million yuan, 9.89 million yuan, and 11.83 million yuan for 2025, 2026, and 2027 respectively [5] Online and Offline Sales Channels - Online sales for women's clothing reached approximately 652 million yuan, a year-on-year increase of 22.55% [9] - Online sales accounted for 46.80% of women's clothing revenue, an increase of 8.8 percentage points [9] - The company is integrating online and offline channels to enhance customer experience and increase repurchase rates [9] Inventory Management - As of September 30, 2025, the net value of women's clothing inventory was approximately 630 million yuan, a year-on-year increase of 13.84% [10] - Inventory less than one year old was approximately 522 million yuan, a year-on-year increase of 23.55% [10]